Poland· PL-100443183
Praluent
A alirocumab product containing alirocumabum, registered in Poland by Sanofi Winthrop Industrie. The same ATC class is registered in 15 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Alirocumab is registered in 15 of 19 countries.
Countries holding a registration under ATC C10AX14 (alirocumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Alirocumab · ATC C10AX14
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of alirocumab costs, country by country.
Normalised to the WHO defined daily dose (5.4 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Alirocumab · price per daily dose (5.4 mg)
USD · FX 28 Sept 2026
- CH Switzerland$16.93
The record
At a glance
URPL (Poland)- Active substance
- Alirocumabum
- Manufacturer
- Sanofi Winthrop Industrie
- Country
- Poland (PL)
- ATC code
- C10AX14
- ATC class
- Alirocumab
- Defined daily dose
- 5.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05909991559830
- gtin05909991559847
- gtin05909991441166
- gtin05909991441173
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Alirocumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPRALUENTSanofi Winthrop Industrie, Gentilly
- BelgiumPraluent 300 mgSanofi Winthrop Industrie
- SpainPRALUENT 300 MG SOLUCION INYECTABLE EN PLUMA PRECARGADASanofi Winthrop Industrie
- IcelandPraluentSanofi Winthrop Industrie
- NorwayPraluentSanofi Winthrop Industrie
- SwedenPraluent 300 mg Injektionsvätska, lösning i förfylld injektionspennaSanofi Winthrop Industrie
- SwitzerlandPraluent 150 mg, solution injectable en stylo prérempliSanofi-Aventis (Suisse) SA
- United StatesPraluentRegeneron Pharmaceuticals, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Praluent
- Liechtenstein · Praluent
- Norway · Praluent
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cbf1e4b3-c2eb-413f-b840-725530823dd3 GET /v1/drugs/cbf1e4b3-c2eb-413f-b840-725530823dd3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań we wstrzykiwaczu",
"source": "urpl",
"strength": "300 mg",
"packaging": "05909991441166 ¦ Rp ¦ EU/1/15/1031/019 ¦ 138151\n1 wstrzykiwacz 2 ml\n05909991441173 ¦ Rp ¦ EU/1/15/1031/020 ¦ 138152\n3 wstrzykiwacze 2 ml\n05909991559830 ¦ Rp ¦ EU/1/15/1031/022 ¦ 159162\n3 wstrzykiwacze 2 ml\n05909991559847 ¦ Rp ¦ EU/1/15/1031/021 ¦ 159163\n1 wstrzykiwacz 2 ml",
"substance": "Alirocumabum 300 mg",
"common_name": "Alirocumabum",
"pl_product_id": "100443183",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about alirocumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.